A new study published in Scientific Reports by scientists at XBiotech highlights the promise of targeting interleukin-1 alpha (IL-1α) to combat metastatic melanoma. Using Flo1-2a—a murine surrogate for XBiotech’s anti-IL-1α monoclonal antibody vilamakitug (Natrunix, XB2001)—researchers demonstrated that neutralizing IL-1α markedly suppressed pulmonary tumor nodule burden and significantly prolonged survival in preclinical mouse models. The therapy effectively disrupted key metastatic and immunosuppressive drivers, downregulating crucial genes and proteins including MMP2, MMP9, VEGF, and PD-L1. These findings support IL-1α blockade as a powerful therapeutic approach for treating advanced, metastatic melanoma.
🔗 Read the full study: https://www.nature.com/articles/s41598-026-66972-6
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.
